Cogent Biosciences
Cogent Biosciences
cogentbio.com

Locations

United States · Cambridge, MA, USA

industry

Biotechnology · DeepTech

Size

51-200 employees

Stage

Other

founded in

2014

Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts.

Something looks off?
Open jobs at Cogent Biosciences
Powered by Getro